NCT06170151View on ClinicalTrials.gov

Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Multiple Myeloma
Interventions
DIAGNOSTIC_TEST

Diagnostic accuracy

evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.

Trial Locations (1)

Unknown

Irccs San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER